When did Pasithea Therapeutics IPO? We use only highly qualified psychiatrist and anesthesiologists, who are assisted by expert registered nurses for their services throughout this innovative treatment. Pasithea Therapeutics Corp. is . Pasithea Therapeutics Corp. . IPO Investment Prospectus [Amended] 2021-09-10 17:15:24. In displaying the. ("IPO") in September 2021. Announces Closing of $24.0 Million Initial Public Offering. From the start, our primary focus has been the creation of an . Industry: Health Care. "Pasithea was founded to improve treatment options for those affected by psychiatric and neurological disorders. Complete Pasithea Therapeutics Corp. stock information by Barron's. View real-time KTTA stock price and news, along with industry-best analysis. S-1/A: IPO . "Pasithea was founded to improve treatment options for those affected by psychiatric and neurological disorders. ("IPO") in September 2021. Security and exchange commission filings for Pasithea Therapeutics Corp.. Insider trades, quarterly, and annual reports. In displaying the. Security Name: Units Security Type: Equity/Derivative Unit Securities Offered: 4,800,000 PriceRange: $5 Discount. Pasithea Therapeutics is a biotechnology company that seeks to solve clinical problems such as mental health. IPO Date: Sep 15, 2021: Industry: Biotechnology: Sector: Health Care: Employees: 3: Contact Details. Pasithea Therapeutics Announces Financial and Business Results for the Fourth Quarter and Full Year 2021 and Business Update for 2022. . By 2027, Pasithea reports the estimated size of the anxiety and depression market to be $19.2 billion; however, estimates could rapidly increase as the pandemic continues. Founders Lawrence Steinman. The warrants are exercisable at 125% of the offering price. Pasithea Therapeutics, a biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders, filed . Pasithea Therapeutics ( NASDAQ: KTTA) intends to raise $17 million from the sale of its common stock in an IPO, according to an amended registration statement. | May 22, 2022 ("IPO") in September 2021. (KTTA) raised $17 million in an initial public offering (IPO) on Wednesday, September 15th 2021. (Note: Pasithea Therapeutics upsized its IPO unit offering at pricing on Sept. 14, 2021, to 4.8 million units, up from 2.9 million units, and priced the units at $5, the low end of its $5-to-$7 range, to raise $24 million.) The UK branch of Pasithea's clinics is operating from a capital light partnership with Zen Healthcare, a leading group of practices with three locations in Marylebone, Holborn and Knightsbridge. About Us World Class Management Team Pasithea is led by Professor Lawrence Steinman and the research is headed up by Dr. Tiago Reis Marques. Current price $2.69/share (as of market close 10-12-21) New NASDAQ listing only a month ago. Pasithea Therapeutics Announces Financial and Business Results for the Fourth Quarter and Full Year 2021 and Business Update for 2022 . Pasithea (KTTA) is a New IPO and is Targeting Treatment-Resistant Depression and PTSD Using Ketamine Infusions. Pasithea Therapeutics Corp. we are a biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders.our biotech operations will focus on developing drugs that target the pathophysiology underlying such disorders rather than symptomatic treatments, with the goal of developing new pharmacological agents Pasithea Therapeutics, a preclinical biotech researching drugs for psychiatric and neuro disorders, raised $24 million by offering 4.8 million units at $5, the low end of the range of $5 to $7. Last Funding Type Post-IPO Equity. miami beach, fla., march 30, 2022 (globe newswire) -- pasithea therapeutics corp. (nasdaq: ktta) ("pasithea" or the "company"), a novel biotechnology company focused on the research and discovery. Company profile for Pasithea Therapeutics Corp. (KTTA) with a description, list of executives, contact details and other key facts. | May 22, 2022 By 2027, Pasithea reports the estimated size of the anxiety and depression market to be $19.2 billion; however, estimates could rapidly increase as the pandemic continues. By 2027, Pasithea reports the estimated size of the anxiety and depression market to be $19.2 billion; however, estimates could rapidly increase as the pandemic continues. In displaying the. Pasithea Therapeutics Corp. (NASDAQ: KTTA) is a biotechnology company focused on treatments for psychiatric and neurological disorders. In displaying the . Pasithea Therapeutics Announces Financial and Business Results for the Fourth Quarter and Full Year 2021 and Business Update for 2022. . Pasithea Therapeutics Corp. . 2022, and an original unit price of $5.00 based on the IPO price, consisting of $4.99 for the share and $0.01 for the warrant. Today's IPO for Pasithea Therapeutics (NASDAQ: KTTA) opened for trading at $4.00 after pricing 4,800,000 units at $5.00 per unit. The Company's Common Stock began trading on The Nasdaq Capital Market on September 15, 2021, under the symbol "KTTA." Pasithea Clinics has clinic partnerships both in the United States and in the United Kingdom to provide IV ketamine treatment. EF Hutton Thinks Pasithea Therapeutics Corp's Stock is Going to Recover Dec. 15, 2021 at 4:11 a.m. September 15, 2021 2:59 pm. . MIAMI (PRWEB) November 29, 2021 As the COVID-19 pandemic continues and the world works to adapt and recover to new ways of living, a new Biotech IPO is hoping to bring more interest into an important health sector: mental health. About Pasithea Therapeutics: KTTA is still at a preclinical stage of development, the . The Group owns approximately 6% of the outstanding shares of Pasithea Therapeutics Corp. ("Pasithea" or the "Company") and to our knowledge represents the single largest shareholding body. 2019-08-212000330103000495681171301 . The firm is developing drug treatments for depressive disorders. Pasithea Therapeutics has partnered with IV Doc to provide in-home ketamine treatments to those with clinical depression and anxiety. MIAMI BEACH, Fla., Sept. 17, 2021 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA . In displaying the financial viability of the space, Pasithea launched a new Biotech IPO on September 15th, and raised $24 million with their initial public offering. The Miami Beach, FL-based company plans to raise $17 million by offering 2.9 million shares and warrants at a price range of $5 to $7. FWP: Free Writing Prospectus. August 6, 2021 Pasithea Therapeutics, a preclinical biotech researching drugs for psychiatric and neuro disorders, announced terms for its IPO on Friday. Pasithea Therapeutics, a new and advanced company has partnered with IV Doc to provide in-home ketamine treatments to patients suffering with clinical depression and . Summary. Pasithea Therapeutics Corp. Financial Information: Market Cap: $55.78mil: Revenues: $0 mil (last 12 months) Net Income . By 2027, Pasithea reports the estimated size of the anxiety and depression market to be $19.2 billion; however, estimates could rapidly increase as the pandemic continues. Address: 1111 Lincoln Road Miami Beach, FL 33139 United States. Phone: Pasithea Therapeutics Corp. has completed an IPO in the amount of $24 million. "Pasithea was founded to . . Pasithea Therapeutics Corp is a biotechnology . Pasithea Therapeutics has filed to raise $17.4 million in an IPO. What is Pasithea Therapeutics' stock symbol? The company issued 2,898,551 shares at $5.00-$7.00 per share. The Miami Beach, FL-based company plans to raise $17 million by offering 2.9 million shares and warrants at a price range of $5 to $7. We are a biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders.Our biotech operations will focus on developing drugs that target the pathophysiology . Search / Go. . Pasithea Therapeutics has priced its IPO of 4.8M units, with each unit consisting of one share of common stock and one warrant to purchase one common share at $5.00/unit, for gross proceeds of ~$24M. Pasithea Therapeutics Corp is a biotech company aiming to solve one of the world's biggest clinical problems: brain disorders. Pasithea Therapeutics Corp. Financial Information: Market Cap: $55.78mil: Revenues: $0 mil (last 12 months) Net Income . (Note: Pasithea Therapeutics upsized its IPO unit offering at pricing on Sept. 14, 2021, to 4.8 million units, up from 2.9 million units, and priced the units at $5, the low end of its $5-to-$7 range, to raise $24 million.) August 6, 2021. September 15, 2021 2:59 pm Pasithea Therapeutics, a biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders, filed its. ET on TipRanks.com With the Obesity Epidemic Bursting at the Seams, This Could Help From the start, our primary focus has been the creation of an . Latest Trade: $1.22 -0.01 (-0.8%) First Day Return: -28.8%. Return from IPO: -75.4%. In displaying the financial viability of the space, Pasithea launched a new Biotech IPO on September 15th, and raised $24 million with their initial public offering. Pasithea Therapeutics Corp. (NASDAQ: KTTA) is a biotechnology company focused on treatments for psychiatric and neurological disorders. miami beach, fla., sept. 14, 2021 (globe newswire) -- pasithea therapeutics corp. ("pasithea" or the "company"), a biotechnology company focused on the research and discovery of new and effective. The future of mental health is here. Pasithea Therapeutics Corp. has completed an IPO in the amount of $24 million. . Dr Tiago Reis Margues CEO of Pasithea Therapeutics Dr. Lawrence Steinman Find the latest Pasithea Therapeutics Corp. (KTTA) stock quote, history, news and other vital information to help you with your stock trading and investing. Pasithea Clinics is committed to providing you with the best, most innovative and effective care possible. Current price $2.69/share (as of market close 10-12-21)New NASDAQ listing only a month ago.Only 13M shares outstanding.Insiders own 52% of the outstanding shares.Growing market sector. Pasithea Clinics is committed to providing you with the best, most innovative and effective care possible. We use only highly qualified psychiatrist and anesthesiologists, who are assisted by expert registered nurses for their services throughout this innovative treatment. Founded Date 2020. Companies; Documents; Forms; Alerts; Stock Ticker Lookup. The warrants KTTAW opened at $0.91. EF Hutton, division of. 2021, Pasithea closed an initial public offering (IPO) that raised $24 million. Announces Pricing of Upsized $24.0 Million Initial Public Offering September 14, 2021 21:04 ET | Source: Pasithea Pasithea The UK branch of Pasithea's clinics is operating from a capital light partnership with Zen Healthcare, a leading group of practices with three locations in Marylebone, Holborn and Knightsbridge. Pasithea Therapeutics trades on the NASDAQ under the ticker symbol "KTTA." Security Name: Units Security Type: Equity/Derivative Unit Securities Offered: 4,800,000 PriceRange: $5 Discount. The company offered 1.9 million more units than anticipated. In displaying the financial viability of the space, Pasithea launched a new Biotech IPO on September 15th, and raised $24 million with their initial public offering. By 2027, Pasithea reports the estimated size of the anxiety and depression market to be $19.2 billion; however, estimates could rapidly increase as the pandemic continues. The warrants are exercisable at 125% of the offering . 2021-08-26 18:26:44. Pasithea Therapeutics recently raised $24 million at its initial public offering ("IPO"). About Pasithea Therapeutics Corp. 1111 LINCOLN ROAD SUITE 500, MIAMI BEACH, Florida, 33139, United States +1 702 514-4174 https://www.pasithea.com. Pasithea Therapeutics ( KTTA) has priced its IPO of 4.8M units, with each unit consisting of one share of common stock and one warrant to purchase one common share at $5.00/unit, for gross proceeds. Operating Status Active. Phone Number 702-514-4174. . Pasithea Therapeutics, a preclinical biotech researching drugs for psychiatric and neuro disorders, announced terms for its IPO on Friday. Legal Name Pasithea Therapeutics Corp. Stock Symbol NASDAQ:KTTA. The company is developing psychiatric. This was reported by Pasithea Therapeutics on November 29, 2021. .